Heidi Henanger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heidi Henanger has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ane Funderud
Institute for Basic Medical Sciences, Department of Nutrition, University of Oslo Medical School, Norway
1 shared publication - Anne-Katrine Kvissel
Department of Nutrition, University of Oslo, Oslo, Norway
1 shared publication - Bjørn Steen Skålhegg
Division for Molecular Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
1 shared publication - Ellen Skarpen
Laboratory for Toxicopathology, Institute of Pathology, Oslo University Hospital, University of Oslo, Oslo, Norway
1 shared publication - Henrik S. Huitfeldt
Institute of Pathology, Rikshospitalet University Hospital, University of Oslo, Norway
1 shared publication - Morten P. Oksvold
Department of Immunology, Institute for Cancer Research, The Radium Hospital, FOBY, Oslo University Hospital, Montebello, 0379, Oslo, Norway.
1 shared publication
Latest Publications
- Open Access
- 1 April 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 16
Epidermal growth factor receptor levels are reduced in mice with targeted disruption of the protein kinase A catalytic subunit
Epidermal Growth Factor Receptor (EGFR) is a key target molecule in current treatment of several neoplastic diseases. Hence, in order to develop and improve current drugs targeting EGFR signalling, an accurate understanding of how this signalling pathway is regulated is required. It has recently been demonstrated that inhibition of cAMP-dependent protein kinase (PKA) induces a ligand-independent internalization of EGFR. Cyclic-AMP-dependent protein kinase consists of a regulatory dimer bound to two catalytic subunits.
- 1 April 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 16
Open AccessEpidermal growth factor receptor levels are reduced in mice with targeted disruption of the protein kinase A catalytic subunit
Epidermal Growth Factor Receptor (EGFR) is a key target molecule in current treatment of several neoplastic diseases. Hence, in order to develop and improve current drugs targeting EGFR signalling, an accurate understanding of how this signalling pathway is regulated is required. It has recently been demonstrated that inhibition of cAMP-dependent protein kinase (PKA) induces a ligand-independent internalization of EGFR. Cyclic-AMP-dependent protein kinase consists of a regulatory dimer bound to two catalytic subunits.